China Sky One Medical, Inc. (中国天字一号医药公司) has obtained the rights to nine new drugs from Shandong Medicine Research & Development Institute, paying 15 million RMB ($2.2 million). The company estimates the nine products will generate $5 million in revenue during 2009. According to China Sky One, the nine products are popular in rural areas of China and have received all necessary SFDA approvals. More details...

Stock Symbol: (NSDQ: CSKI)